NSE, BSE Top gainers & Losers today May 21, 2025: Sensex, Nifty 50 trade positive, BEL, Cipla, Sun Pharma, Tata Steel lead gains, IndusInd & RVNL in red ahead of Q4 results, Dixon slumps
[ad_1] Equity benchmark indices traded in positive territory amid global cues. Sensex traded 269.58 points or 0.33 per cent positive at 81,456.02 as at 12.48
With several moving parts, next six months will be a challenge, says Cipla Chief Umang Vohra
[ad_1] Umang Vohra, Cipla Managing Director and Global Chief Executive Officer The next six months will be challenging, said Cipla Managing Director and Global Chief
US government order to have nil impact on Indian pharma players, says Cipla
[ad_1] Umang Vohra, MD and Global CEO, Cipla The US government’s order to pharma firms to lower the cost of prescription medicines within 30 days
Cipla gets USFDA nod for generic cancer drug
[ad_1] Cipla’s protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for injectable suspension 100 mg/vial | Photo Credit: DANISH SIDDIQUI
Cipla: Better Positioned to Grow and Deal with Tariff Uncertainties
[ad_1] Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product
